The UAE has developed its first AI-discovered drug candidate in under 12 months. It marks a breakthrough in healthcare innovation and showcases how artificial intelligence can accelerate drug discovery processes.
A pharmaceutical breakthrough was unveiled by the Emirates Drug Establishment (EDE) on Thursday, April 23, with the announcement of the UAE’s first fully AI-discovered and developed drug candidate by a research team at Insilico Medicine in Masdar City, Abu Dhabi.
The candidate is known as ISM0387. This chemical targets an enzyme called PRMT5. It employs a method called ‘synthetic lethality’ which improves its selective activity against cancer cells while minimising its impact on healthy cells. The compound demonstrates promising potential in targeting solid tumours, particularly aggressive brain cancers, which are among the most treatment-resistant.
Alex Aliper, Co-founder and President of Insilico Medicine, said: “This achievement marks a turning point in global drug development and shows how effective generative AI can be in improving how drugs are discovered, by reducing time and overcoming traditional challenges.”
The drug candidate has properties that enable effective penetration of the blood–brain barrier. It has shown strong ability to slow or stop tumour growth in early lab studies, and the effect becomes stronger as the dose increases.
Studies have shown clear tumour suppression when administered at a daily dose of 30 mg/kg over 20 days in animal models.
Saeed bin Mubarak Al Hajeri, Minister of State and Chairman of the Emirates Drug Establishment, said, “This progress demonstrates the maturity of a national model that brings together scientific research with regulatory and investment frameworks. It allows us to turn scientific discoveries into real-world applications faster and supports the development of a system that can compete in high-value sectors.”
Also Read: World Health Expo 2026: Organ-on-Chip Unveiled as the Future of Precision Medicine
ISM0387 was developed using Insilico Medicine’s Chemistry42 platform. It has integrated more than 40 generative AI models to analyse complex biological and chemical data. The discovery process was executed within the UAE, from biological target identification and molecular design to optimisation and final nomination of the preclinical candidate (PCC).
This achievement is a testament to how generative AI can speed up the drug discovery process. The research team completed the compound discovery phase in about six months, generating and testing more than 90 potential molecules using advanced AI models. Traditionally, this stage alone can take over four years.
The entire development process, from designing the molecule to selecting it as a drug candidate, was completed in less than 12 months. In comparison, conventional drug development can take more than 10 years and cost over $1 billion to bring a single treatment to market.